Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination

Authors: Alicia T. Widge, Nadine Rouphael, Lisa A. Jackson, Evan J. Anderson, Paul C. Roberts, Mamodikoe Makhene, James D. Chappell, Mark R. Denison, Laura J. Stevens, Andrea J. Pruijssers, Adrian B. McDermott, Britta Flach, Bob C. Lin, Nicole A. Doria‐Rose, Sijy O’Dell, Stephen D. Schmidt, Kathleen M. Neuzil, Hamilton Bennett, Brett Leav, Mat Makowski, Jim Albert, Kaitlyn Cross, Venkata Viswanadh Edara, Katharine Floyd, Mehul S. Suthar, Wendy Buchanan, Catherine J. Luke, Julie E. Ledgerwood, John R. Mascola, Barney S. Graham, John H. Beigel - New England Journal of Medicine, NEJM 2020 cited by 829

Immunogenicity and the mRNA-1273 SARS-CoV-2 Vaccine Thirty-four adults received two 100-μg injections of the mRNA-1273 SARS-CoV-2 vaccine, and serum anti–spike protein and neutralizing antibody tit...